Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
Moleculin Biotech, Inc. Adriano Treve 40+ year career at Roche founded on dedication to bringing new innovative medicines to patients...
Cancer
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide’s potential ability to enhance the effectiveness of immunotherapyBASKING...
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture...
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all...
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Company to participate in investor conferences in July and AugustVANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc....
Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement
ROCKVILLE, Md. and SUZHOU, China, July 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage...
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +12% USD) with core operating income1 up...
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer...
AAJ Capital 3 Corp. Announces Definitive Agreement for Qualifying Transaction with XRP Healthcare M&A Holding Inc.
VANCOUVER, BC and DUBAI, UAE, July 16, 2025 /PRNewswire/ -- AAJ Capital 3 Corp. (TSXV: AAAJ.P) ("AAJ"), a capital pool company...
Pivot Bio Expands World-Class Scientific Advisory Board to Advance the Future of Crop Nutrition
Top global experts in crop nutrition, agronomy, and sustainable agriculture join Pivot Bio's Scientific Advisory Board to guide innovation and...
SandboxAQ and iOncologi Partner to Accelerate Brain Cancer Treatment with AI-driven Drug Discovery For Glioblastoma
This collaboration leverages AI-driven molecular design and deep tech immunotherapy expertise to advance a transformative mRNA-based treatment to the clinic...
Virtua Health Successfully Goes Live on Oracle Cloud with Alithya as Strategic Implementation Partner
ALPHARETTA, Ga., July 16, 2025 /PRNewswire/ - Alithya is proud to announce the successful go-live of Oracle Cloud Enterprise Resource...
Vivid Dx Appoints Diagnostics Veteran John Sperzel as Chief Executive Officer and Board Member
OXFORD, United Kingdom, July 16, 2025 (GLOBE NEWSWIRE) -- Vivid Dx, a precision diagnostics company transforming pathogen detection and antimicrobial...
CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY
Kuala Lumpur, Malaysia, July 16, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”),...
Silexion Therapeutics Announces 1-for-15 Reverse Share Split
Trading on split-adjusted basis will begin at market open on July 29, 2025. This adjustment is expected to help Silexion...
Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement
CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”),...
LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements
PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW),...
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined...
Qualigen Granted New Patents Covering 25 Countries
CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company” or “Qualigen”) is announcing an...
Jaya Biosciences Receives Patent Notices of Allowance in Japan, China, and Singapore for Novel Methods of Treating Neurological Diseases, including Alzheimer’s, Further Strengthening its Global Intellectual Property Portfolio
- Patent allowances in Japan, China and Singapore support Jaya Biosciences’ commitment to addressing unmet needs in neurodegeneration in global...